Home
/
TScan Therapeutics, Inc.
/
Financials
/
Quarterly
TScan Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that TScan Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.51M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$3.08M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$2.17M
May 6, 2025
Q3
2025
Sep 30, 2024
$1.05M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$536.0K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$566.0K
May 6, 2025
Q3
2024
Sep 30, 2023
$3.89M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$3.15M
Aug 12, 2024
Q1
2024
Mar 31, 2023
$6.80M
May 13, 2024
Q3
2023
Sep 30, 2022
$3.36M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$4.06M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$3.02M
May 10, 2023
Q3
2022
Sep 30, 2021
$2.41M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$2.85M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$2.03M
May 12, 2022
Q3
2021
Sep 30, 2020
$290.0K
Nov 10, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($35.71M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($36.95M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($34.13M)
May 6, 2025
Q3
2025
Sep 30, 2024
($29.89M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($31.66M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($30.14M)
May 6, 2025
Q3
2024
Sep 30, 2023
($23.00M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($24.05M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($22.56M)
May 13, 2024
Q3
2023
Sep 30, 2022
($16.25M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($15.10M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($16.16M)
May 10, 2023
Q3
2022
Sep 30, 2021
($15.84M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($10.67M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($7.91M)
May 12, 2022
Q3
2021
Sep 30, 2020
($7.17M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($5.61M)
Aug 19, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($37.05M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($38.65M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($36.25M)
May 6, 2025
Q3
2025
Sep 30, 2024
($32.62M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($34.11M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($31.37M)
May 6, 2025
Q3
2024
Sep 30, 2023
($24.75M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($24.61M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($22.74M)
May 13, 2024
Q3
2023
Sep 30, 2022
($16.58M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($15.25M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($16.16M)
May 10, 2023
Q3
2022
Sep 30, 2021
($15.84M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($10.68M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($7.92M)
May 12, 2022
Q3
2021
Sep 30, 2020
($7.17M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($5.62M)
Aug 19, 2021